Astec LifeSciences (Small Cap - High Growth) Share Target 2025, 2026 To 2035
|
Astec LifeSciences Limited |
|||
|
Price: ₹765.45 (+5.44%) | ||
| 52 Week Low: ₹647.50 52 Week High: ₹1,474.40 |
|||
| Market Capital: 2,060.56 Crore (Smallcap) | |||
| Basic Materials -> Agricultural Inputs | |||
Show Table of Contents
Table of Contents
- 1: Approach 1: Technical Analysis Paired With Price Action
- 1.1: Astec LifeSciences Share Price Target For 2025
- 1.1.1: Astec LifeSciences Share Price Target Table For 2025
- 1.1.2: Short-Term Technical Outlook
- 1.2: Astec LifeSciences Share Price Target For 2026
- 1.2.1: Astec LifeSciences Share Price Target Table For 2026
- 1.2.2: Long-Term Technical Outlook
- 2: Approach 2: Machine Learning By Studying Historical Prices
- 2.1: Astec LifeSciences Share Price Target Chart and Table From 2025, 2026, 2027 to 2035
- 3: Astec LifeSciences Brief Company Overview
- 4: Astec LifeSciences Financial Performance
- 4.0.1: Is Astec LifeSciences A Good Buy For Long Term?
Astec LifeSciences, a Small Cap company in the Agricultural Inputs Industry has delivered 62.4% returns in 5-year, making it a High Growth stock.
To predict the Astec LifeSciences's future market prices, we harnessed 2 dynamic approaches:
Approach 1: Technical Analysis Paired With Price Action
Approach 2: Machine Learning By Studying Historical Prices
Approach 1: Technical Analysis Paired With Price Action
Astec LifeSciences Share Price Target For 2025
The line chart displays the monthly closing prices of Astec LifeSciences with a black line. The green line shows three potential target prices for 2025, while the red line indicates three potential Stop Loss levels.
For detailed target and stop loss values for Astec LifeSciences shares in 2025, see the table below.
Astec LifeSciences Share Price Target Table For 2025
| Level | Value | Analysis |
|---|---|---|
| 2025 Target 3 | 909.9 (+18.87%) | Price Action: 11 Feb 2025 High |
| 2025 Target 2 | 900.0 (+17.57%) | Price Action: 04 Mar 2024 Low |
| 2025 Target 1 | 889.55 (+16.21%) | Price Action: 01 Mar 2024 Low |
| Current Price | 765.45 | Astec LifeSciences's share price as of 25 Feb 2025 |
| Stop Loss 1 | 706.9 (-7.65%) | Price Action: Jul 2018 High |
| Stop Loss 2 | 694.0 (-9.34%) | Price Action: Dec 2016 High |
| Stop Loss 3 | 684.0 (-10.65%) | Price Action: May 2017 High |
Short-Term Technical Outlook
Current Technical Position: Astec LifeSciences is displaying bearish momentum trading below key moving averages.
Key Technical Level: The 25-day moving average at ₹887.47 serves as the nearest technical reference point.
Historical Returns: 3-month: -28.36% | 6-month: -36.46% | 1-year: -13.97%
Astec LifeSciences Share Price Target For 2026
The line chart displays the monthly closing prices of Astec LifeSciences with a black line. The green line shows three potential target prices for 2026, while the red line indicates three potential Stop Loss levels.
For detailed target and stop loss values for Astec LifeSciences shares in 2026, see the table below.
Astec LifeSciences Share Price Target Table For 2026
| Level | Value | Analysis |
|---|---|---|
| 2026 Target 3 | 1329.9 (+73.73%) | Price Action: 29 Jul 2024 High |
| 2026 Target 2 | 1316.6 (+72%) | Price Action: 12 Jul 2024 Low |
| 2026 Target 1 | 1303.0 (+70.22%) | Price Action: 16 Nov 2023 High |
| Current Price | 765.45 | Astec LifeSciences's share price as of 25 Feb 2025 |
| Stop Loss 1 | 624.13 (-18.47%) | Price Action: Chart |
| Stop Loss 2 | 617.89 (-19.28%) | Price Action: Chart |
| Stop Loss 3 | 606.77 (-20.74%) | Price Action: Chart |
Long-Term Technical Outlook
52-Week Range Analysis: Astec LifeSciences is currently trading near its 52-week low of ₹647.5, indicating potential value opportunity.
Long-Term Trend Analysis: The stock is in a bearish long-term trend, trading below key long-term moving averages.
Long-Term Performance: 1-year: -13.97% | 3-year: -50.37% | 5-year: +62.36%
Stay ahead of the market! Get instant alerts on crucial market breakouts. Don't miss out on key opportunities!
Your phone number will be HIDDEN to other users.
Approach 2: Machine Learning By Studying Historical Prices
Astec LifeSciences Share Price Target Chart and Table From 2025, 2026, 2027 to 2035
| Year | Target 1 | Target 1 YoY Chg % | Target 2 |
|---|---|---|---|
| Current Price | ₹765.45 | ||
| 2025 | ₹1,633.34 | +113.38% | ₹1,657.84 |
| 2026 | ₹1,882.38 | +15.24% | ₹1,910.62 |
| 2027 | ₹2,102.33 | +11.68% | ₹2,133.86 |
| 2028 | ₹2,488.93 | +18.38% | ₹2,526.26 |
| 2029 | ₹2,621.16 | +5.31% | ₹2,660.48 |
| 2030 | ₹3,000.17 | +14.45% | ₹3,045.17 |
| 2031 | ₹3,372.20 | +12.4% | ₹3,422.78 |
| 2032 | ₹4,039.99 | +19.8% | ₹4,100.59 |
| 2033 | ₹4,501.72 | +11.42% | ₹4,569.25 |
| 2034 | ₹4,936.88 | +9.66% | ₹5,010.93 |
| 2035 | ₹5,376.08 | +8.89% | ₹5,456.72 |
Note: Target 1 and Target 2 represent price levels that the stock is most likely to achieve during the respective year, based on machine learning algorithms analyzing historical price patterns and market behavior. These predictions are generated through comprehensive analysis of the stock's historical data using advanced ML models.
Astec LifeSciences Brief Company Overview
Company Overview: Astec LifeSciences Limited Established in 1994, Astec LifeSciences Limited is a renowned manufacturer, distributor, and exporter of agrochemical active ingredients and pharmaceutical intermediates. Headquartered in Mumbai, India, the company is a...
subsidiary of Godrej Agrovet Limited and has a strong market presence. Astec LifeSciences Limited is committed to providing high-quality products to its customers and has a wide range of offerings, including: Triazole fungicides Heterocyclic herbicides Sulfonyl urea herbicides Synthetic pyrethroids Fluorinated intermediates Heterocyclic mercaptans Heterocyclic sulfonyl chloridesAstec LifeSciences Financial Performance
| Metric | Value | Description |
|---|---|---|
| Market Capital | 2,060.56 Crore | Market valuation of Astec LifeSciences's shares. |
| Revenue (TTM) | 372.92 Crore | Total revenue generated by Astec LifeSciences over the past twelve months. |
| Net Income (TTM) | -103.59 Crore | Net Profit or Loss after all the expenses over the past twelve months. |
| Operating Margin | -31.67% | Income from operations as a percentage of revenue, before taxes and interest. |
| Profit Margin | -27.78% | Net income as a percentage of revenue, after all expenses. |
| Revenue Growth (Quarterly) |
-11.1% | Change in revenue compared to the previous quarter. |
| Debt-to-Equity (D/E) Ratio |
171.53 | Company's total debt divided by total shareholder equity. |
| Total Debt | 500.45 Crore | Sum of Astec LifeSciences's current & long-term financial obligations. |
| Total Cash | 2.06 Crore | Total amount of liquid funds available to Astec LifeSciences. |
| Beta | 0.33 | Beta is less than 1 indicating that the Astec LifeSciences's price is less volatile than the market. |
Is Astec LifeSciences A Good Buy For Long Term?
Astec LifeSciences, a small-cap stock with a market capitalization of ₹2,060.56 crore, presents a mixed picture for long-term investors. While its five-year return of 100.89% is encouraging, the company is currently unprofitable, reporting a net loss of ₹103.59 crore in the last twelve months (TTM) and a negative profit margin of -27.78%. High debt (₹500.45 crore) against minimal cash (₹2.06 crore) and negative returns over the past year (-12.90%) raise significant concerns. Therefore, based on this data, Astec LifeSciences is not a good buy for the long term. Further investigation is warranted.
Disclaimer: The information provided on this page is for educational purposes only and should not be considered as financial advice. Historical performance data and technical analysis cannot guarantee future results. Stock investments are subject to market risks. Please consult with a qualified financial advisor before making any investment decisions.
All stock data shown is sourced from publicly available information and while we strive for accuracy, we cannot guarantee the absolute accuracy of all figures. Users should verify critical information from official sources before making investment decisions.
